Fundamental Analysis of BIOVIE INC(NASDAQ:BIVI) stock

Fundamental Rating

BIVI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. BIVI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BIVI is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

BIVI had negative earnings in the past year.

BIVI had a negative operating cash flow in the past year.

In the past 5 years BIVI always reported negative net income.

BIVI had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

BIVI has a worse Return On Assets (-126.06%) than 81.06% of its industry peers.

Looking at the Return On Equity, with a value of -190.33%, BIVI is doing worse than 68.32% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-126.06%
ROE	-190.33%
ROIC	N/A

ROA(3y)-1103.91%

ROA(5y)-1006.53%

ROE(3y)-1559.62%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BIVI so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for BIVI has been reduced compared to 1 year ago.

Compared to 5 years ago, BIVI has more shares outstanding

BIVI has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -22.43, we must say that BIVI is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -22.43, BIVI is not doing good in the industry: 87.61% of the companies in the same industry are doing better.

There is no outstanding debt for BIVI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-22.43

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

BIVI has a Current Ratio of 2.95. This indicates that BIVI is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 2.95, BIVI is doing worse than 65.49% of the companies in the same industry.

BIVI has a Quick Ratio of 2.95. This indicates that BIVI is financially healthy and has no problem in meeting its short term obligations.

BIVI has a worse Quick ratio (2.95) than 63.19% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	2.95
Quick Ratio	2.95

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

BIVI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -288.27%.

EPS 1Y (TTM)-288.27%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-141.28%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 23.11% on average over the next years. This is a very strong growth

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y22.85%

EPS Next 2Y30.83%

EPS Next 3Y25.16%

EPS Next 5Y23.11%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BIVI. In the last year negative earnings were reported.

Also next year BIVI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

BIVI's earnings are expected to grow with 25.16% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y30.83%

EPS Next 3Y25.16%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

BIVI does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

BIOVIE INC

NASDAQ:BIVI (12/20/2024, 8:00:01 PM)

After market: 1.94 +0.04 (+2.11%)

1.9

-0.18 (-8.65%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)09-09 2024-09-09/amc

Earnings (Next)02-11 2025-02-11/bmo

Inst Owners6%

Inst Owner Change-96.48%

Ins Owners1.24%

Ins Owner Change0%

Market Cap33.76M

Analysts82.86

Price Target5.1 (168.42%)

Short Float %11.98%

Short Ratio0.24

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-83.33%

PT rev (3m)-83.33%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	2.4
P/tB	2.53
EV/EBITDA	N/A

EPS(TTM)-15.6

EYN/A

EPS(NY)-4.5

Fwd EYN/A

FCF(TTM)-1.09

FCFYN/A

OCF(TTM)-1.09

OCFYN/A

SpS0

BVpS0.79

TBVpS0.75

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-126.06%
ROE	-190.33%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-1103.91%

ROA(5y)-1006.53%

ROE(3y)-1559.62%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.95
Quick Ratio	2.95
Altman-Z	-22.43

F-Score6

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-288.27%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-141.28%

EPS Next Y22.85%

EPS Next 2Y30.83%

EPS Next 3Y25.16%

EPS Next 5Y23.11%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y46.03%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-62.56%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-62.56%

OCF growth 3YN/A

OCF growth 5YN/A

BIOVIE INC (BIVI)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens